Clinical Trial

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-08-31; most recent amendment 2025-02-06.
Status change: Recruiting → Active, Not Recruiting 2025-02-06
Status change: Not Yet Recruiting → Recruiting 2022-07-19
Trial Details
NCT Number NCT05032040
Lead Sponsor Xencor, Inc.
Collaborators: ICON plc
Conditions Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 170 participants
Start Date 2022-07-21
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-07